Dean H. Bergy Appointed Chairman of the Board; Brian K. Hutchison Remains CEO
ALACHUA, Fla. (May 10, 2011) - RTI Biologics Inc.
(RTI) (Nasdaq: RTIX), a leading provider of orthopedic and other biologic implants, announced today that the board of directors has separated the roles of chairman of the board and chief executive officer (CEO).
Dean H. Bergy assumed the role of chairman of the board of directors effective May 5, 2011, while Brian K. Hutchison remains CEO of the company and a member of the board of directors.
" RTI has always strived to maintain high corporate governance standards, and the board has evaluated its leadership structure each year," said Dean H. Bergy, RTI's chairman of the board.
"The board of directors decided to proactively make this change based on an evaluation of current best practices of corporate governance."
"Dean is an exceptional executive and has deep experience with the intricacies of the healthcare and medical device industries," said Brian K. Hutchison, RTI's CEO.
Bergy, 51, joined RTI's Board of Directors in July 2010.
public accounting and executive management experience provides RTI's board of directors with valuable financial reporting, compliance, and accounting and controls experience.
Bergy currently serves as advisor to the chief financial officer at Stryker, a position he has held since April 2009.
He served the previous six years as Stryker's vice president and chief financial officer.
Prior to that, Bergy served as vice president of finance and chief accounting officer, vice president of finance for Stryker's Medical Division, and started his tenure with Stryker in 1994 as the corporate controller.
Previous to joining Stryker, he worked with Ernst & Young and Price Waterhouse.
Bergy earned a bachelor's degree in business administration from University of Michigan in Ann Arbor and completed the Program for Management Development from Harvard Business School.